Risdiplam is the sole orally administered drug accredited with the treatment of SMA. It had been FDA accredited in 2020 to be used in patients two months of age and older, and it features being an SMN2 gene splicing modifier bringing about larger levels of SMN protein. Oral administration is https://billya975sxb8.smblogsites.com/profile